Regencell Bioscience is an early-stage bioscience company that develops Traditional Chinese Medicine (TCM) formulas to treat Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD) in children and adolescents. The company is in the research and development stage and does not currently generate product revenue. Its core product candidate is a standardized, oral liquid TCM formula designed to improve neurological function and address ADHD and ASD simultaneously. Regencell has completed early-stage, uncontrolled efficacy studies in Hong Kong and is preparing for further clinical testing through industry partnerships. The company's business model centers on commercializing its formula as a proprietary Chinese medicine in Hong Kong, seeking to sell the product over the counter upon regulatory approval from the Hong Kong Chinese Medicines Board. Long term, Regencell plans to expand internationally into markets such as the U.S. as either a drug or dietary supplement, while also exploring formula applications for other neurological conditions.